‘Unprecedented’ EMA Response To COVID-19 Must Be Sustained
Post Approval Setting Matters Too, Says New Agency Head Emer Cooke
Executive Summary
The agility, flexibility and transparency that the European Medicines Agency has adopted during the development and assessment of COVID-19 products will have to continue after treatments and vaccines are on the market, says the soon-to-be new head of the agency, Emer Cooke.
You may also be interested in...
Coronavirus Notebook: Moderna Claims 94.5% Vaccine Efficacy, Janssen Starts Second ENSEMBLE Trial
The European Medicines Agency has begun a rolling review of Moderna’s mRNA vaccine, and its new executive director, Emer Cooke, has taken up her role with a promise to make tackling COVID-19 her “number one priority.”
Incoming EMA Chief Throws Weight Behind Antimicrobial Resistance Fight
Antimicrobial resistance, the lack of new antibiotics, and preserving the effectiveness of existing ones are high on the agenda for the soon-to-be new head of the European Medicines Agency, Emer Cooke.
Access And Affordability Are Key, Says New EMA Head
Ensuring patients have access to approved medicines is a key priority for Emer Cooke, the soon-to-be new head of the European Medicines Agency. Cooke says she will probably be a very different type of “captain” of the “wonderful ship” that is the EMA.